Cargando…

Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China

PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopatho...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yiqun, Li, Qiao, Mo, Hongnan, Guan, Xiuwen, Lin, Shaoyan, Wang, Zijing, Chen, Yimeng, Zhang, Ye, Zhang, Dainan, Chen, Shanshan, Cai, Ruigang, Wang, Jiayu, Luo, Yang, Fan, Ying, Yuan, Peng, Zhang, Pin, Li, Qing, Ma, Fei, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736978/
https://www.ncbi.nlm.nih.gov/pubmed/33310633
http://dx.doi.org/10.1016/j.breast.2020.11.021
_version_ 1783622871824728064
author Li, Yiqun
Li, Qiao
Mo, Hongnan
Guan, Xiuwen
Lin, Shaoyan
Wang, Zijing
Chen, Yimeng
Zhang, Ye
Zhang, Dainan
Chen, Shanshan
Cai, Ruigang
Wang, Jiayu
Luo, Yang
Fan, Ying
Yuan, Peng
Zhang, Pin
Li, Qing
Ma, Fei
Xu, Binghe
author_facet Li, Yiqun
Li, Qiao
Mo, Hongnan
Guan, Xiuwen
Lin, Shaoyan
Wang, Zijing
Chen, Yimeng
Zhang, Ye
Zhang, Dainan
Chen, Shanshan
Cai, Ruigang
Wang, Jiayu
Luo, Yang
Fan, Ying
Yuan, Peng
Zhang, Pin
Li, Qing
Ma, Fei
Xu, Binghe
author_sort Li, Yiqun
collection PubMed
description PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopathological features, treatment and survival information were extracted. Multivariable logistic and Cox regression were performed to determine factors predictive of brain metastases at MBC diagnosis and survival, respectively. RESULTS: Brain metastases occurred in ninety patients (4.3%) at MBC diagnosis, and in 27 patients (2.5%), 42 patients (7.2%) and 21 patients (5.2%) with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR + HER2-), HER2-positive and triple negative breast cancer (TNBC), respectively. HER2-positive subtype (OR = 2.38; 95% CI 1.40–4.04; p < 0.0001), TNBC subtype (OR = 1.89; 95% CI 1.02–3.51; p = 0.005), and metastases to all three sites of bone, liver and lungs (OR = 3.23; 95% CI 1.52–6.87; p = 0.002) were shown to increase the risk of BM at MBC diagnosis. Median survival after BM was 23.7 months. First-line tyrosine kinase inhibitors (TKI) improved survival compared to trastuzumab-based regimen (44.9 vs 35.4 months, p = 0.09). Factors that independently decreased BM death risk were ECOG<2, brain metastases only and multidisciplinary treatment. CONCLUSION: HER2-positive and TNBC subtypes have a higher incidence of BM at initial MBC diagnosis. Brain screening might be considered in patients with HER2-positive disease at MBC diagnosis, and further prospective randomized study is warranted.
format Online
Article
Text
id pubmed-7736978
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77369782020-12-18 Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China Li, Yiqun Li, Qiao Mo, Hongnan Guan, Xiuwen Lin, Shaoyan Wang, Zijing Chen, Yimeng Zhang, Ye Zhang, Dainan Chen, Shanshan Cai, Ruigang Wang, Jiayu Luo, Yang Fan, Ying Yuan, Peng Zhang, Pin Li, Qing Ma, Fei Xu, Binghe Breast Original Article PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopathological features, treatment and survival information were extracted. Multivariable logistic and Cox regression were performed to determine factors predictive of brain metastases at MBC diagnosis and survival, respectively. RESULTS: Brain metastases occurred in ninety patients (4.3%) at MBC diagnosis, and in 27 patients (2.5%), 42 patients (7.2%) and 21 patients (5.2%) with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR + HER2-), HER2-positive and triple negative breast cancer (TNBC), respectively. HER2-positive subtype (OR = 2.38; 95% CI 1.40–4.04; p < 0.0001), TNBC subtype (OR = 1.89; 95% CI 1.02–3.51; p = 0.005), and metastases to all three sites of bone, liver and lungs (OR = 3.23; 95% CI 1.52–6.87; p = 0.002) were shown to increase the risk of BM at MBC diagnosis. Median survival after BM was 23.7 months. First-line tyrosine kinase inhibitors (TKI) improved survival compared to trastuzumab-based regimen (44.9 vs 35.4 months, p = 0.09). Factors that independently decreased BM death risk were ECOG<2, brain metastases only and multidisciplinary treatment. CONCLUSION: HER2-positive and TNBC subtypes have a higher incidence of BM at initial MBC diagnosis. Brain screening might be considered in patients with HER2-positive disease at MBC diagnosis, and further prospective randomized study is warranted. Elsevier 2020-12-04 /pmc/articles/PMC7736978/ /pubmed/33310633 http://dx.doi.org/10.1016/j.breast.2020.11.021 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Li, Yiqun
Li, Qiao
Mo, Hongnan
Guan, Xiuwen
Lin, Shaoyan
Wang, Zijing
Chen, Yimeng
Zhang, Ye
Zhang, Dainan
Chen, Shanshan
Cai, Ruigang
Wang, Jiayu
Luo, Yang
Fan, Ying
Yuan, Peng
Zhang, Pin
Li, Qing
Ma, Fei
Xu, Binghe
Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
title Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
title_full Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
title_fullStr Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
title_full_unstemmed Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
title_short Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
title_sort incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in china
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736978/
https://www.ncbi.nlm.nih.gov/pubmed/33310633
http://dx.doi.org/10.1016/j.breast.2020.11.021
work_keys_str_mv AT liyiqun incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT liqiao incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT mohongnan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT guanxiuwen incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT linshaoyan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT wangzijing incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT chenyimeng incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT zhangye incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT zhangdainan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT chenshanshan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT cairuigang incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT wangjiayu incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT luoyang incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT fanying incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT yuanpeng incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT zhangpin incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT liqing incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT mafei incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina
AT xubinghe incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina